Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04157192
Other study ID # RCB : 2019-A00588-49
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 27, 2022
Est. completion date October 2024

Study information

Verified date April 2023
Source Centre Hospitalier Universitaire de Nimes
Contact Marc FREARD, Dr.
Phone 06.19.42.18.37
Email marc.freard@chu-nimes.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acupuncture has been a means of treating headaches and migraine since 2002 and is now a World Health Organisation-recognized prophylactic treatment for migraine. Brain activation/de-activation via acupuncture modifies the haemodynamic responses in the brain which may impact the sensorial, cognitive and affective dimensions of pain. Randomized studies on patients suffering from aura-free migraine have shown that the painkilling effect of regular acupuncture sessions on the cerebral substratum, compared with simulated sham-type acupuncture, can reduce the frequency of bouts of migraine, number of days with headaches and also their intensity. Modifications to the white matter (WM) and grey matter (GM) occur after repeated sessions of acupuncture treatment for pain and these are observable via magnetic resonance imaging (MRI). It is a very sensitive technique and often used to detect functional and structural brain changes.


Description:

Since 2002, acupuncture has been employed as a method for treating headaches and migraine. It is recognized by the World Health Organisation (WHO), and is now part of the prophylactic treatments for migraine. Brain activations/de-activation via acupuncture lead to a modification of haemodynamic responses in the brain which may impact the sensorial, cognitive and affective dimensions of pain. Randomized studies on patients who suffer from migraine without aura have shown that the painkilling effect of repeated acupuncture sessions on the cerebral substratum, compared with simulated sham-type acupuncture, make it possible to reduce the frequency of bouts of migraine, the number of days of headaches, and the intensity of the bouts. Following repeated sessions of acupuncture treatment for pain, modifications occur in the white matter (WM) and in the grey matter (GM) and these may be observed by magnetic resonance imaging (MRI) which is a highly sensitive technique and very often used to detect functional brain changes and/or subtle abnormalities.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 2024
Est. primary completion date May 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - All patients with two to eight bouts of migraine without an aura per month - All patient aged (=) 18 to (=) 60 years old - All patients who have not had a bout of migraine in the last 24 hours - All patients who have given free informed consent and have signed the consent form. - All patients who are affiliated to or beneficiaries of a health insurance scheme - All patients available for a two-month follow-up Exclusion Criteria: - All patients with migraine which is secondary to a neurological, neuropsychiatric, or vascular disorder - All patients suffering from diabetes - All patients with a past history of alcohol or drug abuse - All patients with contraindications for an MRI scan - All patients on antidepressants or Botox. - All patients already taking part in Category 1 research involving the human person - All patients on an exclusion period determined by another study - All patients placed under judicial protection, guardianship, or supervision - All patients for whom it is impossible to give the subject clear information - All patients who are pregnant, about to give birth or breastfeeding - All patient who have received botulinum toxin in the past year - All patient who have undergone antidepressant treatment in the last 2 months - All patient who have started a background migraine treatment for less than 3 months - All patient who have more than 14 migraine days per month

Study Design


Intervention

Other:
Real acupuncture
The patient will be treated for migraine with real acupuncture.
Sham acupuncture (placebo group)
Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.

Locations

Country Name City State
France Marc FREARD Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Regional homogeneity map in Interventional group patients BEFORE first real acupuncture session. Regional homogeneity in patients treated via real acupuncture (Interventional group) is computed with functional magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - Start of therapy
Primary Regional homogeneity map in Interventional group patients AFTER first real acupuncture session. Regional homogeneity in patients treated via real acupuncture (Interventional group) is computed with functional magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - Start of therapy
Primary Regional homogeneity map in Placebo group patients BEFORE first real acupuncture session. Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - Start of therapy
Primary Regional homogeneity map in Placebo group patients AFTER first real acupuncture session. Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - Start of therapy
Primary Regional homogeneity map in Interventional group patients BEFORE last real acupuncure session Regional homogeneity in patients treated via acupuncture (Interventional group) is is computed with functional magnetic resonance imaging Sixty days after inclusion in the trial (Day 60) - end of therapy
Primary Regional homogeneity map in Interventional group patients AFTER last real acupuncure session Regional homogeneity in patients treated via acupuncture (Interventional group) is computed with functional magnetic resonance imaging Sixty days after inclusion in the trial (Day 60) - end of therapy
Primary Regional homogeneity map of Placebo group patients BEFORE last placebo acupuncture session Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging Sixty days after inclusion in the trial (Day 60) - end of therapy
Primary Regional homogeneity map of Placebo group patients AFTER last placebo acupuncture session Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging Sixty days after inclusion in the trial (Day 60) - end of therapy
Secondary Mean diffusivity of White Matter of Interventional group patients BEFORE first real acupuncture session The mean diffusivity of White Matter of Interventional group patients is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Mean diffusivity of White Matter of Interventional group patients AFTER first real acupuncture session The mean diffusivity of White Matter of Interventional group patients is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Mean diffusivity of White Matter of Placebo group patients BEFORE first placebo acupuncture session The mean diffusivity of White Matter of Placebo group patients is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Mean diffusivity of White Matter of Placebo group patients AFTER first placebo acupuncture session The mean diffusivity of White Matter of Placebo group patients is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Mean diffusivity of White Matter of Interventional group patients BEFORE last real acupuncture session The mean diffusivity of White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Mean diffusivity of White Matter of Interventional group patients AFTER last real acupuncture session The mean diffusivity of White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Mean diffusivity of White Matter of Placebo group patients BEFORE last placebo acupuncture session The mean diffusivity of White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Mean diffusivity of White Matter of Placebo group patients AFTER last placebo acupuncture session The mean diffusivity of White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Radial diffusivity of the White Matter in Interventional group patients BEFORE first real acupuncture session Radial diffusivity of the White Matter of Interventional group patients is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Radial diffusivity of the White Matter in Interventional group patients AFTER first real acupuncture session Radial diffusivity of the White Matter in the Interventional group patients is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Radial diffusivity of the White Matter in Placebo group patients BEFORE first placebo acupuncture session Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Radial diffusivity of the White Matter in Placebo group patients AFTER first placebo acupuncture session Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Radial diffusivity of the White Matter in Interventional group patients BEFORE last real acupuncture session Radial diffusivity of the White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Radial diffusivity of the White Matter in Placebo group patients AFTER last real acupuncture session Radial diffusivity of the White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Radial diffusivity of the White Matter in Interventional group patients BEFORE last placebo acupuncture session Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Radial diffusivity of the White Matter in Placebo group patients AFTER last placebo acupuncture session Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Fractional anisotropy of the White Matter in Interventional group patients BEFORE first real acupuncture session Fractional anisotropy of patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Fractional anisotropy of the White Matter in Interventional group patients AFTER first real acupuncture session Fractional anisotropy of patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Fractional anisotropy of the White Matter in Placebo group patients BEFORE first placebo acupuncture session Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Fractional anisotropy of the White Matter in Placebo group patients AFTER first placebo acupuncture session Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging At the inclusion visit (Vinc) on Day 0 - start of therapy
Secondary Fractional anisotropy of the White Matter in Interventional group patients BEFORE last real acupuncture session Fractional anisotropy in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Fractional anisotropy of the White Matter in Interventional group patients AFTER last real acupuncture session Fractional anisotropy in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Fractional anisotropy of the White Matter in Placebo group patients BEFORE last placebo acupuncture session Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Fractional anisotropy of the White Matter in Placebo group patients AFTER first placebo acupuncture session Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging 60 days after the initial inclusion visit (Day 60) - end of therapy
Secondary Change in number of days with migraine per month - Interventional group BEFORE treatment The number of days with migraine per month will be measured according to the days noted on a calendar At the inclusion visit (Vinc) on Day 0
Secondary Change in number of days with migraine per month - Interventional group AFTER treatment The number of days with migraine per month will be measured according to the days noted on a calendar At the end of the study (on Day 90)
Secondary Change in number of days with migraine per month - Placebo group BEFORE treatment The number of days with migraine per month will be measured according to the days noted on a calendar At the inclusion visit (Vinc) on Day 0
Secondary Change in number of days with migraine per month - Placebo group AFTER treatment The number of days with migraine per month will be measured according to the days noted on a calendar At the end of the study (on Day 90)
Secondary Pain BEFORE treatment in the Interventional group The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson. The VAS is a simple numerical scale for measuring the intensity of pain. It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm). The patient slides the cursor to give the intensity of pain that he/she feels. The amount of pain felt will be reported on the migraine calendar. At the inclusion visit (Vinc) on Day 0
Secondary Pain AFTER treatment in the Interventional group The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson. The VAS is a simple numerical scale for measuring the intensity of pain. It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm). The patient slides the cursor to give the intensity of pain that he/she feels. The amount of pain felt will be reported on the migraine calendar. At the end of the study (on Day 90)
Secondary Pain BEFORE treatment in the Placebo group The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson. The VAS is a simple numerical scale for measuring the intensity of pain. It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm). The patient slides the cursor to give the intensity of pain that he/she feels. The amount of pain felt will be reported on the migraine calendar. At the inclusion visit (Vinc) on Day 0
Secondary Pain AFTER treatment in the Placebo group The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson. The VAS is a simple numerical scale for measuring the intensity of pain. It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm). The patient slides the cursor to give the intensity of pain that he/she feels. The amount of pain felt will be reported on the migraine calendar. At the end of the study (on Day 90)
Secondary Impact of migraine on the Interventional group patients' Quality of Life (QOL) BEFORE treatment The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6). This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations. At the inclusion visit (Vinc) on Day 0
Secondary Impact of migraine on the Interventional group patients' Quality of Life (QOL) AFTER treatment The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6). This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations. At the end of the study on Day 90
Secondary Impact of migraine on the Placebo group patients' Quality of Life (QOL) BEFORE treatment. The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6). This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations. At the inclusion visit (Vinc) on Day 0
Secondary Impact of migraine on the Placebo group patients' Quality of Life (QOL) AFTER treatment. The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6). This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations. At the end of the study on Day 90
See also
  Status Clinical Trial Phase
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01687660 - Acupuncture for Migraine Prophylaxis N/A
Completed NCT00363532 - Functional MRI (fMRI) in CGRP Induced Migraine N/A
Completed NCT00123201 - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Phase 2
Completed NCT04406649 - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3
Completed NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Phase 1
Recruiting NCT05565001 - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. N/A
Completed NCT04533568 - Ibuprofen in Migraine Patients Phase 4
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Recruiting NCT05416476 - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Phase 3
Completed NCT04636359 - Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging. N/A
Completed NCT00534560 - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Phase 2
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Completed NCT00380263 - PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow N/A
Completed NCT00334178 - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Phase 3
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Recruiting NCT06414044 - Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Completed NCT03472378 - Can DFN-15 Terminate Migraine With Allodynia? Phase 2
Recruiting NCT05211154 - Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine Phase 4